C URRENT OPINION The control of lipid-induced inflammation by macrophages
Evrim Jaccard a and Christian Widmann b Type 2 diabetes (T2M) arises when insulin resistance and b cell dysfunction develop in the context of over-nutrition and weight gain [1] . Several mechanisms have been proposed to explain the evolution towards diabetes, including oxidative stress, endoplasmic reticulum stress, lipotoxicity, and glucotoxicity [2] . Although individual studies pinpoint the importance of each of these factors in the pathogenesis of diabetes in rodents, progression towards T2M in humans is polyfactorial. Inflammation in the hypothalamus, liver, adipose tissue, and the pancreas arises now as a potential link between these conditions. Two recent studies shed important information on how macrophages control lipidinduced inflammation.
Macrophages have been the first immune cells identified in mouse [3] and human [4] adipose tissue. An increase in the number of macrophages has also been demonstrated in pancreatic islets of T2M patients, as well as in diet-induced animal models of obesity [5 & ]. Macrophages infiltrating visceral adipose tissue belong to the M1 proinflammatory myeloid subtype, whereas those infiltrating subcutaneous adipose tissue are predominantly of the anti-inflammatory M2 subtype [6 & ]. This observation might in part explain the reason why some obese individuals remain metabolically healthy, whereas others develop diabetes and cardiovascular disease. What dictates the differentiation of macrophages into the M1 or M2 subtypes was poorly understood.
A study published by the laboratory of Shizuo Akira has now characterized Trib1, an adaptor protein of the pseudokinase tribble family involved in protein degradation, as a critical factor for macrophage differentiation into the M2 subtype [7 && ]. Trib1-deficient mice showed a defect in M2-like macrophage generation (as well as eosinophil differentiation). These mice had a diminished adipose tissue mass but augmented lipolysis, and this was accompanied by decreased glucose tolerance. Reconstitution of the Trib1-deficient mice with Trib1 þ/þ M2 macrophages abrogated these defects. This indicates that lipodystrophy and glucose intolerance in the Trib1 knock-out mice were the consequences of a lack in M2 macrophages. Possibly, production of interleukin-10 by M2 macrophages is important in this context, as this cytokine is known to protect against insulin resistance [8]. This study may have important implications for humans as genome-wide association studies have implicated Trib1 in metabolic disorders [9] .
In contrast to M2 macrophages, M1 macrophages promote inflammation. Work from the laboratory of Roger Davis now shows that the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathway in those macrophages is responsible for the induction of inflammation and insulin resistance triggered by obesity [10 && ]. Macrophage-specific JNK deficiency led to improved glucose tolerance and reduced inflammation in mice fed a high-fat diet. This prevented the accumulation of M1 macrophages in adipose tissue but, interestingly, did not affect the infiltration of M2 macrophages in these tissues. It thus appears that peripheral insulin resistance or b cell dysfunction can be caused by free fatty acids and JNK-induced polarization of macrophages towards the M1 subtype in fat tissue. This is an example of inter-organ cross-talk participating in the development of metabolic diseases. This work identifies Trib1 as a critical factor for the differentiation of the M2 subtype of macrophages. Furthermore, this study highlights the importance of this macrophage subtype in counteracting the proinflammatory effects of macrophages of the M1 subtype. Obesity, by altering the equilibrium between these two cell populations in favour of the latter subtype, induces sustained inflammation and decreased glucose tolerance. Drugs capable of increasing the number or the activity of M2like macrophages have, therefore, a clear antidiabetic potential. Signalling through JNK in insulin-sensitive tissues leads to decreased glucose tolerance and diabetes onset. Mechanistically, JNKs promote insulin resistance by phosphorylating the insulin receptor substrate adaptor proteins, hampering efficient signalling downstream of the insulin receptor. JNK signalling in the central nervous system also favours insulin resistance by promoting obesity. The authors of this study now provide evidence that JNKs contribute to insulin resistance by favouring the differentiation of macrophages into the proinflammatory M1 subtype. Macrophage-specific JNK deficiency was found to be associated with the secretion of anti-inflammatory cytokines by epididymal adipose tissue and improved overall glucose tolerance. These results point towards a pivotal role played by macrophages in modulating adipose inflammation and peripheral insulin sensitivity. It was suggested earlier that targeting the JNK MAPK pathway could be efficacious against obesity and insulin resistance development by restoring insulin sensitivity in the central nervous system, skeletal muscles, and adipocytes. The present study indicates that inhibiting JNK MAPK signalling in another cell type -the macrophages -also contributes to the prevention of obesity-induced insulin resistance by limiting inflammation in adipose tissue. Hence, JNK inhibitory drugs may generate independent beneficial actions against obesity-mediated dysfunctions by targeting, insulin-sensitive tissues, neurons, and cells that control inflammation. How overnutrition triggers inflammation and the mechanisms by which FFAs produce their deleterious so-called 'lipotoxic' effects are thoroughly treated in this perspective article. The causal link between gastrointestinal microbiota and the development of insulin resistance is also discussed in detail.
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